BNP Paribas Financial Markets Acquires 17,387 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

BNP Paribas Financial Markets lifted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 69.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 42,310 shares of the biopharmaceutical company’s stock after buying an additional 17,387 shares during the period. BNP Paribas Financial Markets’ holdings in Intra-Cellular Therapies were worth $3,534,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Intra-Cellular Therapies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company’s stock worth $811,928,000 after acquiring an additional 93,107 shares in the last quarter. Norges Bank bought a new position in shares of Intra-Cellular Therapies in the 4th quarter worth about $268,347,000. Invesco Ltd. grew its stake in shares of Intra-Cellular Therapies by 2.9% in the 4th quarter. Invesco Ltd. now owns 3,077,174 shares of the biopharmaceutical company’s stock valued at $257,006,000 after buying an additional 87,582 shares during the period. Franklin Resources Inc. grew its stake in shares of Intra-Cellular Therapies by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 1,776,880 shares of the biopharmaceutical company’s stock valued at $148,405,000 after buying an additional 23,594 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of Intra-Cellular Therapies by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,716,829 shares of the biopharmaceutical company’s stock valued at $143,434,000 after buying an additional 8,528 shares during the period. 92.33% of the stock is owned by institutional investors.

Intra-Cellular Therapies Price Performance

Intra-Cellular Therapies stock opened at $131.87 on Thursday. Intra-Cellular Therapies, Inc. has a 52 week low of $64.09 and a 52 week high of $131.98. The company’s 50 day moving average price is $131.76 and its two-hundred day moving average price is $113.06. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. On average, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently commented on ITCI. StockNews.com began coverage on Intra-Cellular Therapies in a research note on Thursday. They issued a “hold” rating for the company. Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Mizuho downgraded Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their target price for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Eleven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Intra-Cellular Therapies currently has an average rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.